Radiation Oncology

HER2-negative breast cancer

Questions discussed in this category

What are your top takeaways in Breast Cancer from ESMO 2025?

7 Answers available

What are your top takeaways in Medical Oncology from SABCS 2024?

13 Answers available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Sep 06

Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

The New England journal of medicine, 2024 Dec 11

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer.

N. Engl. J. Med.,

Pembrolizumab for Early Triple-Negative Breast Cancer.

Lancet Oncol., 2020 Mar 12

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.

Annals of oncology : official journal of the European Society for Medical Oncology, 2025 Oct 18

Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial.

The New England journal of medicine, 2025 Oct 19

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer.

Future oncology (London, England), 2023 Aug 01

TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer.

J. Clin. Oncol., 2020 Sep 20

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).

The New England journal of medicine, 2024 Mar 21

Ribociclib plus Endocrine Therapy in Early Breast Cancer.

The New England journal of medicine, 2025 May 31

Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer.

The New England journal of medicine, 2025 Oct 29

Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer.

Related Topics in Radiation Oncology